Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Chemotherapy-induced Neutropenia 1

Interventions

Carboplatin 315 Paclitaxel 303 Cisplatin 250 Docetaxel 238 pembrolizumab 230 Gemcitabine 214 Pemetrexed 158 Capecitabine 147 Rituximab 144 Bevacizumab 142 Dexamethasone 125 Fluorouracil 121 Cyclophosphamide 102 Trastuzumab 100 Doxorubicin 96 Nivolumab 93 Prednisone 92 Oxaliplatin 90 atezolizumab 75 Leucovorin 72 durvalumab 69 130-nm albumin-bound paclitaxel 68 Injections 66 Lenalidomide 63 Irinotecan 62 Bortezomib 56 Letrozole 54 Topotecan 53 Fulvestrant 53 Drug Therapy 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × balugrastim × Clear all

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡